The Cambridge and Boston biotech corridor has become one of the most competitive drug discovery environments in the world, and research laboratories operating here face mounting pressure to do more with every instrument on their floor.
Genera, Retisoft’s lab automation scheduling software, connects directly to laboratory instruments, enabling them to perform tasks that scientists would otherwise execute manually and repeatedly. For automation engineers and scientists across Massachusetts, the best lab automation scheduling software is no longer a convenience; it is a strategic necessity.
Cambridge’s biotech density continues to grow, with new drug discovery programs launching across the Kendall Square ecosystem at a pace that strains existing laboratory capacity. Genera addresses this pressure by connecting to instruments and orchestrating the specific tasks that consume scientists’ time, freeing those scientists to focus on higher-value research decisions.
Automation engineers in Cambridge drug discovery labs frequently cite repetitive microplate reading cycles as a primary bottleneck. Genera connects directly to the microplate reader, instructs it to perform the read, and manages the sequence without requiring a scientist to remain present. The scientist walks away and returns to the results, not to a waiting instrument.
Boston-area research facilities have increasingly reported that proprietary hardware ecosystems drive integration costs upward over time, locking procurement teams into single-vendor upgrade paths. Genera’s open API connectivity allows the software to communicate with a laboratory’s LIMS and with instruments from multiple vendors, replacing closed hardware loops with a coordinated, vendor-neutral orchestration layer.
Vendor lock-in is a structural risk for any high-throughput screening lab that has assembled instruments from multiple manufacturers over successive budget cycles. Genera acts as the connective layer between those instruments, orchestrating movement and task execution without requiring the laboratory to standardize on a single hardware brand.
Genera integrates with liquid handlers from multiple vendors, instructing robotic arms to move, aspirate, and dispense according to the workflow logic defined in the software. Retisoft does not sell liquid-handling instruments; the software connects to instruments the lab already owns. This agnostic approach delivers meaningfully greater workflow flexibility than closed scheduling environments that restrict instrument choice.
Complex drug discovery assays in Massachusetts high-throughput screening labs rarely follow a perfectly linear sequence. Genera’s event-driven logic monitors instrument status in real time and dynamically adjusts task sequencing, replacing static run-lists with responsive orchestration. When an instrument signals an error or delay, Genera recovers automatically rather than halting the entire run. Ready to see this in action for your workflow? Request a local workflow integration consultation with the Retisoft team.
New England’s research landscape has shifted toward modular laboratory architecture, with facilities in Boston, Cambridge, and surrounding hubs assembling best-of-breed instrument fleets rather than committing to monolithic platforms. Genera is built for exactly this environment, providing a centralized orchestration layer that spans diverse instrument types.
Genera’s extensive instrument driver library enables plug-and-play connectivity across a wide range of laboratory equipment, reducing the integration effort required when a new instrument joins the fleet. Centralized access controls within Genera allow laboratory managers to define which users can trigger which automated tasks, supporting operational integrity across shared research environments.
A cell culture team performing straightforward scheduling tasks can deploy Genera in a lightweight configuration to automate a handful of repetitive steps without requiring an enterprise-scale implementation. As research programs grow, the same platform scales to orchestrate complex, multi-instrument workflows across an entire facility. Retisoft builds what it calls Automationships with local partners, providing the dedicated support that transforms software deployment into a long-term regional collaboration.
Massachusetts drug discovery organizations evaluate scheduling software against demanding criteria: instrument compatibility, workflow flexibility, and the ability to evolve alongside changing research programs. Genera consistently meets these criteria because it is designed around instrument connectivity and task automation rather than hardware sales.
Leading pharmaceutical and biotech institutions have deployed Genera across global sites, validating the platform’s reliability in high-stakes drug discovery environments. This global deployment record gives Massachusetts procurement teams confidence that local investments in Genera are backed by proven performance at scale. The platform evolves continuously alongside changing laboratory workflows, ensuring that today’s configuration remains relevant as research priorities shift.
Retisoft’s Automationship model pairs agnostic scheduling software with dedicated support, giving New England biotech teams a partner rather than simply a vendor. Genera provides centralized, real-time visibility into system status across connected instruments, allowing automation engineers to monitor the entire laboratory floor from a single interface. This positions Genera as the central brain of the laboratory, coordinating every automated task across the instrument fleet.
Boston laboratories that invest in open, instrument-agnostic orchestration today are better positioned to absorb new instrument acquisitions, expanded assay libraries, and evolving drug discovery mandates without having to rebuild their automation stack from scratch.
Evaluating readiness for an upgraded orchestration layer begins with an honest audit of where manual intervention is most frequent.
These indicators reveal where Genera’s instrument connectivity would deliver the most immediate operational benefit.
Retisoft provides dedicated support for New England biotechnology companies, combining deep knowledge of regional laboratory environments with an open architecture that reduces the burden of specialized training on local teams.
Genera’s vendor-neutral design means your team learns one orchestration platform rather than a new interface for every instrument brand. Schedule a demonstration for your local laboratory and see how Genera connects to your specific instrument fleet to automate the tasks that are slowing your scientists down today.
Latest Blogs
